CN109195602B - 用作免疫调节剂的对称或半对称化合物 - Google Patents
用作免疫调节剂的对称或半对称化合物 Download PDFInfo
- Publication number
- CN109195602B CN109195602B CN201780024052.4A CN201780024052A CN109195602B CN 109195602 B CN109195602 B CN 109195602B CN 201780024052 A CN201780024052 A CN 201780024052A CN 109195602 B CN109195602 B CN 109195602B
- Authority
- CN
- China
- Prior art keywords
- methyl
- amino
- biphenyl
- hydroxyethyl
- methoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 113
- 239000002955 immunomodulating agent Substances 0.000 title description 2
- 229940121354 immunomodulator Drugs 0.000 title description 2
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 claims abstract 3
- -1 {3'- [ (4- { [ (2S) -2-carboxypiperidin-1-yl ] methyl } -3, 5-dimethoxyphenoxy) methyl ] -2,2' -dimethyl- [1,1 '-biphenyl ] -3-yl } methoxy Chemical group 0.000 claims description 127
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 102
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 56
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 55
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 52
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 38
- 235000010290 biphenyl Nutrition 0.000 claims description 26
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 26
- 230000003993 interaction Effects 0.000 claims description 21
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims description 14
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 13
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 13
- 229910052736 halogen Inorganic materials 0.000 claims description 11
- 150000002367 halogens Chemical class 0.000 claims description 11
- 150000003254 radicals Chemical class 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 8
- LMGABZSWLRKREG-UHFFFAOYSA-N 2-[[4-[[3-[[4-(azetidin-1-ylmethyl)-2-methylphenoxy]methyl]-2-chlorophenyl]methoxy]-3-methylphenyl]methylamino]ethanol Chemical compound N1(CCC1)CC1=CC(=C(OCC=2C(=C(C=CC=2)COC2=C(C=C(C=C2)CNCCO)C)Cl)C=C1)C LMGABZSWLRKREG-UHFFFAOYSA-N 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 claims description 7
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- FKUGAPMFOWQYAO-UHFFFAOYSA-N 1-[[4-[[3-[[4-(azetidin-1-ylmethyl)-2-methylphenoxy]methyl]-2-chlorophenyl]methoxy]-3-methylphenyl]methyl]azetidine Chemical compound CC1=C(OCC2=CC=CC(COC3=C(C)C=C(CN4CCC4)C=C3)=C2Cl)C=CC(CN2CCC2)=C1 FKUGAPMFOWQYAO-UHFFFAOYSA-N 0.000 claims description 5
- RLYDKFGREKRKLQ-UHFFFAOYSA-N 2-[[4-(azetidin-1-ylmethyl)-2-methylphenoxy]methyl]-6-[[4-(azetidin-1-ylmethyl)phenoxy]methyl]benzonitrile Chemical compound N1(CCC1)CC1=CC(=C(OCC2=C(C#N)C(=CC=C2)COC2=CC=C(C=C2)CN2CCC2)C=C1)C RLYDKFGREKRKLQ-UHFFFAOYSA-N 0.000 claims description 5
- ADQKQAZVACKHPN-UHFFFAOYSA-N 1-[[4-[[3-[3-[[4-[(2-hydroxyethylamino)methyl]-2-methylphenoxy]methyl]-2-methylphenyl]-2-methylphenyl]methoxy]-2-methoxyphenyl]methyl]azetidin-3-ol Chemical compound COc1cc(OCc2cccc(c2C)-c2cccc(COc3ccc(CNCCO)cc3C)c2C)ccc1CN1CC(O)C1 ADQKQAZVACKHPN-UHFFFAOYSA-N 0.000 claims description 4
- RFZZRQVVCHIAHA-UHFFFAOYSA-N 2-[[4-[(2-hydroxyethylamino)methyl]-3,5-dimethoxyphenoxy]methyl]-6-[3-[[4-[(2-hydroxyethylamino)methyl]-3,5-dimethoxyphenoxy]methyl]phenyl]benzonitrile Chemical compound COc1cc(OCc2cccc(c2)-c2cccc(COc3cc(OC)c(CNCCO)c(OC)c3)c2C#N)cc(OC)c1CNCCO RFZZRQVVCHIAHA-UHFFFAOYSA-N 0.000 claims description 4
- IQODZKORUMDYEX-UHFFFAOYSA-N 2-[[4-[[3-[3-[[4-[(2-hydroxyethylamino)methyl]-3,5-dimethoxyphenoxy]methyl]-2-methylphenyl]-2-methylphenyl]methoxy]-2,6-dimethoxyphenyl]methylamino]ethanol Chemical compound CC1=C(C=CC=C1COC1=CC(=C(C(=C1)OC)CNCCO)OC)C1=C(C(=CC=C1)COC1=CC(=C(C(=C1)OC)CNCCO)OC)C IQODZKORUMDYEX-UHFFFAOYSA-N 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- LNIRJAYUEMYYLP-UHFFFAOYSA-N 2,6-bis[[4-[(2-hydroxyethylamino)methyl]-3-methoxyphenoxy]methyl]benzonitrile Chemical compound OCCNCC1=C(C=C(OCC2=C(C#N)C(=CC=C2)COC2=CC(=C(C=C2)CNCCO)OC)C=C1)OC LNIRJAYUEMYYLP-UHFFFAOYSA-N 0.000 claims description 3
- OXBVQSJSNDTUEX-UHFFFAOYSA-N 2-[[4-[[3-[3-[[4-[(2-hydroxyethylamino)methyl]-2-methylphenoxy]methyl]-2-methylphenyl]-2-methylphenyl]methoxy]-3-methylphenyl]methylamino]ethanol Chemical compound OCCNCC1=CC(=C(OCC=2C(=C(C=CC=2)C2=C(C(=CC=C2)COC2=C(C=C(C=C2)CNCCO)C)C)C)C=C1)C OXBVQSJSNDTUEX-UHFFFAOYSA-N 0.000 claims description 3
- OCGQFJONOXEGFJ-UHFFFAOYSA-N 2-[[4-[[3-[3-[[4-[(2-hydroxyethylamino)methyl]-3,5-dimethoxyphenoxy]methyl]-2-methylphenyl]phenyl]methoxy]-2,6-dimethoxyphenyl]methylamino]ethanol Chemical compound COc1cc(OCc2cccc(c2)-c2cccc(COc3cc(OC)c(CNCCO)c(OC)c3)c2C)cc(OC)c1CNCCO OCGQFJONOXEGFJ-UHFFFAOYSA-N 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 2
- DRLWWPPGDRZHJZ-UHFFFAOYSA-N 2-[[4-(azetidin-1-ylmethyl)-2-methylphenoxy]methyl]-6-[[4-[[(4-oxoazetidin-2-yl)methylamino]methyl]phenoxy]methyl]benzonitrile Chemical compound N1(CCC1)CC1=CC(=C(OCC2=C(C#N)C(=CC=C2)COC2=CC=C(C=C2)CNCC2NC(C2)=O)C=C1)C DRLWWPPGDRZHJZ-UHFFFAOYSA-N 0.000 claims description 2
- CQNSOHJNAMCENY-UHFFFAOYSA-N 2-[[4-(azetidin-1-ylmethyl)-3,5-dimethoxyphenoxy]methyl]-6-[3-[[4-(azetidin-1-ylmethyl)-3,5-dimethoxyphenoxy]methyl]phenyl]benzonitrile Chemical compound COc1cc(OCc2cccc(c2)-c2cccc(COc3cc(OC)c(CN4CCC4)c(OC)c3)c2C#N)cc(OC)c1CN1CCC1 CQNSOHJNAMCENY-UHFFFAOYSA-N 0.000 claims description 2
- WLPATYNQCGVFFH-UHFFFAOYSA-N 2-phenylbenzonitrile Chemical compound N#CC1=CC=CC=C1C1=CC=CC=C1 WLPATYNQCGVFFH-UHFFFAOYSA-N 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- SRFIBLNJZJVANQ-UHFFFAOYSA-N N-[2-[[4-[[3-[[4-(azetidin-1-ylmethyl)-2-methylphenoxy]methyl]-2-cyanophenyl]methoxy]phenyl]methylamino]ethyl]acetamide Chemical compound N1(CCC1)CC1=CC(=C(OCC=2C(=C(C=CC=2)COC2=CC=C(C=C2)CNCCNC(C)=O)C#N)C=C1)C SRFIBLNJZJVANQ-UHFFFAOYSA-N 0.000 claims description 2
- VIEGLSKDJACDLB-UHFFFAOYSA-N N-[[4-[[3-[3-[[4-[(cyclopropylamino)methyl]-3,5-dimethoxyphenoxy]methyl]-2-methylphenyl]-2-methylphenyl]methoxy]-2,6-dimethoxyphenyl]methyl]cyclopropanamine Chemical compound COc1cc(OCc2cccc(c2C)-c2cccc(COc3cc(OC)c(CNC4CC4)c(OC)c3)c2C)cc(OC)c1CNC1CC1 VIEGLSKDJACDLB-UHFFFAOYSA-N 0.000 claims description 2
- 239000004305 biphenyl Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- LVMMJPHWRYDKAD-UHFFFAOYSA-N 2-[2-cyano-3-[[4-[(2-hydroxyethylamino)methyl]-2-methylphenoxy]methyl]phenyl]-6-[[4-[(2-hydroxyethylamino)methyl]-2-methylphenoxy]methyl]benzonitrile Chemical compound OCCNCC1=CC(=C(OCC2=C(C(=CC=C2)C=2C(=C(C=CC2)COC2=C(C=C(C=C2)CNCCO)C)C#N)C#N)C=C1)C LVMMJPHWRYDKAD-UHFFFAOYSA-N 0.000 claims 1
- RUFMIPJTKQNEIU-UHFFFAOYSA-N 2-[2-cyano-3-[[4-[(2-hydroxyethylamino)methyl]phenoxy]methyl]phenyl]-6-[[4-[(2-hydroxyethylamino)methyl]phenoxy]methyl]benzonitrile Chemical compound OCCNCc1ccc(OCc2cccc(-c3cccc(COc4ccc(CNCCO)cc4)c3C#N)c2C#N)cc1 RUFMIPJTKQNEIU-UHFFFAOYSA-N 0.000 claims 1
- MUYIWCAOXMPACR-UHFFFAOYSA-N 2-[[3,5-dimethoxy-4-[[(4-oxoazetidin-2-yl)methylamino]methyl]phenoxy]methyl]-6-[3-[[3,5-dimethoxy-4-[[(4-oxoazetidin-2-yl)methylamino]methyl]phenoxy]methyl]phenyl]benzonitrile Chemical compound COc1cc(OCc2cccc(c2)-c2cccc(COc3cc(OC)c(CNCC4CC(=O)N4)c(OC)c3)c2C#N)cc(OC)c1CNCC1CC(=O)N1 MUYIWCAOXMPACR-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract description 16
- 125000000623 heterocyclic group Chemical group 0.000 abstract description 12
- 150000004945 aromatic hydrocarbons Chemical class 0.000 abstract description 7
- 125000000753 cycloalkyl group Chemical group 0.000 abstract description 5
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract description 3
- 239000004215 Carbon black (E152) Substances 0.000 abstract description 2
- 229930195733 hydrocarbon Natural products 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 148
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 85
- 239000000203 mixture Substances 0.000 description 75
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 62
- 239000000243 solution Substances 0.000 description 59
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 57
- 235000019439 ethyl acetate Nutrition 0.000 description 50
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 48
- 239000000047 product Substances 0.000 description 40
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 39
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 37
- 238000006243 chemical reaction Methods 0.000 description 35
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 34
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 34
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 33
- 239000012044 organic layer Substances 0.000 description 27
- 238000000034 method Methods 0.000 description 26
- 239000012043 crude product Substances 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 21
- 239000000741 silica gel Substances 0.000 description 21
- 229910002027 silica gel Inorganic materials 0.000 description 21
- GZPHSAQLYPIAIN-UHFFFAOYSA-N 3-pyridinecarbonitrile Chemical compound N#CC1=CC=CN=C1 GZPHSAQLYPIAIN-UHFFFAOYSA-N 0.000 description 20
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 20
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 20
- 150000001299 aldehydes Chemical class 0.000 description 19
- 238000003756 stirring Methods 0.000 description 19
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 18
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
- 229910052938 sodium sulfate Inorganic materials 0.000 description 18
- 238000004440 column chromatography Methods 0.000 description 17
- 239000003208 petroleum Substances 0.000 description 17
- 239000007832 Na2SO4 Substances 0.000 description 16
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000000543 intermediate Substances 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- 238000005160 1H NMR spectroscopy Methods 0.000 description 14
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 14
- 125000003118 aryl group Chemical group 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 14
- 210000001744 T-lymphocyte Anatomy 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- 238000006268 reductive amination reaction Methods 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- 239000012071 phase Substances 0.000 description 12
- 239000011734 sodium Substances 0.000 description 12
- 239000003112 inhibitor Substances 0.000 description 11
- 239000003446 ligand Substances 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 239000000539 dimer Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 10
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 238000002953 preparative HPLC Methods 0.000 description 9
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 9
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 8
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 230000002441 reversible effect Effects 0.000 description 8
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 8
- FJDQFPXHSGXQBY-UHFFFAOYSA-L Cs2CO3 Substances [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 7
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical class [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 7
- 229910020889 NaBH3 Inorganic materials 0.000 description 7
- 239000012267 brine Substances 0.000 description 7
- 229910000024 caesium carbonate Inorganic materials 0.000 description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000009739 binding Methods 0.000 description 6
- SACNIGZYDTUHKB-UHFFFAOYSA-N ditert-butyl-[2-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane Chemical group CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C(C)(C)C)C(C)(C)C SACNIGZYDTUHKB-UHFFFAOYSA-N 0.000 description 6
- 239000003480 eluent Substances 0.000 description 6
- 238000003032 molecular docking Methods 0.000 description 6
- 238000010791 quenching Methods 0.000 description 6
- 238000004809 thin layer chromatography Methods 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- BAKYASSDAXQKKY-UHFFFAOYSA-N 4-Hydroxy-3-methylbenzaldehyde Chemical compound CC1=CC(C=O)=CC=C1O BAKYASSDAXQKKY-UHFFFAOYSA-N 0.000 description 5
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 5
- 239000012448 Lithium borohydride Substances 0.000 description 5
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- MKQQTCSBXHAYQL-UHFFFAOYSA-N methyl 3-bromo-2-methylbenzoate Chemical compound COC(=O)C1=CC=CC(Br)=C1C MKQQTCSBXHAYQL-UHFFFAOYSA-N 0.000 description 5
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- WXAMPPKWLGNFSG-UHFFFAOYSA-N 2-[[4-[[4-[[4-[(2-hydroxyethylamino)methyl]-3,5-dimethoxyphenoxy]methyl]indazol-1-yl]methyl]phenyl]methylamino]ethanol Chemical compound OCCNCC1=CC=C(C=C1)CN1N=CC2=C(C=CC=C12)COC1=CC(=C(C(=C1)OC)CNCCO)OC WXAMPPKWLGNFSG-UHFFFAOYSA-N 0.000 description 4
- WIESCUABKRFDOL-UHFFFAOYSA-N 2-[[4-[[5-[[4-[(2-hydroxyethylamino)methyl]-3-methoxyphenoxy]methyl]-4-methylthiophen-3-yl]methoxy]-2-methoxyphenyl]methylamino]ethanol Chemical compound OCCNCC1=C(C=C(OCC=2C(=C(SC=2)COC2=CC(=C(C=C2)CNCCO)OC)C)C=C1)OC WIESCUABKRFDOL-UHFFFAOYSA-N 0.000 description 4
- WBIZZNFQJPOKDK-UHFFFAOYSA-N 4-hydroxy-2-methoxybenzaldehyde Chemical compound COC1=CC(O)=CC=C1C=O WBIZZNFQJPOKDK-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- WMBONEJDEKTXOA-UHFFFAOYSA-N [3-[3-(hydroxymethyl)-2-methylphenyl]-2-methylphenyl]methanol Chemical compound CC1=C(CO)C=CC=C1C1=CC=CC(CO)=C1C WMBONEJDEKTXOA-UHFFFAOYSA-N 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- HGQULGDOROIPJN-UHFFFAOYSA-N azetidin-1-ium;chloride Chemical compound Cl.C1CNC1 HGQULGDOROIPJN-UHFFFAOYSA-N 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 230000006916 protein interaction Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 4
- 235000019798 tripotassium phosphate Nutrition 0.000 description 4
- JDBAPBAPAIVFAP-UHFFFAOYSA-N 1-(bromomethyl)-3-[3-(bromomethyl)-2-methylphenyl]-2-methylbenzene Chemical group CC1=C(CBr)C=CC=C1C1=CC=CC(CBr)=C1C JDBAPBAPAIVFAP-UHFFFAOYSA-N 0.000 description 3
- JJXDEDQEHDNMSR-UHFFFAOYSA-N 1-[[4-[(3-bromo-2-methylphenyl)methoxy]-2-methoxyphenyl]methyl]azetidin-3-ol Chemical compound COC1=C(CN2CC(O)C2)C=CC(OCC2=C(C)C(Br)=CC=C2)=C1 JJXDEDQEHDNMSR-UHFFFAOYSA-N 0.000 description 3
- HORQAOAYAYGIBM-UHFFFAOYSA-N 2,4-dinitrophenylhydrazine Chemical compound NNC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O HORQAOAYAYGIBM-UHFFFAOYSA-N 0.000 description 3
- FWRLWJQQDYDXKM-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[3-(hydroxymethyl)phenyl]benzonitrile Chemical compound OCC1=CC=CC(=C1)C1=C(C#N)C(CO)=CC=C1 FWRLWJQQDYDXKM-UHFFFAOYSA-N 0.000 description 3
- DILISPNYIVRDBP-UHFFFAOYSA-N 2-[3-[2-(2-hydroxypropylamino)pyrimidin-4-yl]-2-naphthalen-2-ylimidazol-4-yl]acetonitrile Chemical compound OC(CNC1=NC=CC(=N1)N1C(=NC=C1CC#N)C1=CC2=CC=CC=C2C=C1)C DILISPNYIVRDBP-UHFFFAOYSA-N 0.000 description 3
- RSKXCVXHHUFLDB-UHFFFAOYSA-N 2-[[4-(azetidin-1-ylmethyl)-2-methylphenoxy]methyl]-6-[[4-[(2-hydroxyethylamino)methyl]phenoxy]methyl]benzonitrile Chemical compound N1(CCC1)CC1=CC(=C(OCC2=C(C#N)C(=CC=C2)COC2=CC=C(C=C2)CNCCO)C=C1)C RSKXCVXHHUFLDB-UHFFFAOYSA-N 0.000 description 3
- UVHOGRZCEPHKGI-UHFFFAOYSA-N 2-[[4-[[4-[[4-[(2-hydroxyethylamino)methyl]-3,5-dimethoxyphenoxy]methyl]indol-1-yl]methyl]phenyl]methylamino]ethanol Chemical compound OCCNCC1=C(C=C(OCC2=C3C=CN(C3=CC=C2)CC2=CC=C(C=C2)CNCCO)C=C1OC)OC UVHOGRZCEPHKGI-UHFFFAOYSA-N 0.000 description 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- GFQLJLOLPRNHKI-UHFFFAOYSA-N 4-[(3-bromo-2-methylphenyl)methoxy]-2-methoxybenzaldehyde Chemical compound BrC=1C(=C(COC2=CC(=C(C=O)C=C2)OC)C=CC=1)C GFQLJLOLPRNHKI-UHFFFAOYSA-N 0.000 description 3
- QAURGHQLADKPJW-UHFFFAOYSA-N 4-[[2-chloro-3-[(4-formyl-2-methylphenoxy)methyl]phenyl]methoxy]-3-methylbenzaldehyde Chemical compound CC1=C(C=CC(=C1)C=O)OCC2=C(C(=CC=C2)COC3=C(C=C(C=C3)C=O)C)Cl QAURGHQLADKPJW-UHFFFAOYSA-N 0.000 description 3
- HZWPJAZIRZFCGX-UHFFFAOYSA-N 4-hydroxy-2,6-dimethoxybenzaldehyde Chemical compound COC1=CC(O)=CC(OC)=C1C=O HZWPJAZIRZFCGX-UHFFFAOYSA-N 0.000 description 3
- AVBARORPQMEWPR-UHFFFAOYSA-N 6-chloro-2-methoxypyridine-3-carbaldehyde Chemical compound COC1=NC(Cl)=CC=C1C=O AVBARORPQMEWPR-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 208000037581 Persistent Infection Diseases 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 3
- 230000006044 T cell activation Effects 0.000 description 3
- 230000006052 T cell proliferation Effects 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000012131 assay buffer Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 3
- YBXBWBBVLXZQBJ-UHFFFAOYSA-N n-[2-(5-hydroxy-2-methyl-1h-indol-3-yl)ethyl]-2-methoxyacetamide Chemical compound C1=C(O)C=C2C(CCNC(=O)COC)=C(C)NC2=C1 YBXBWBBVLXZQBJ-UHFFFAOYSA-N 0.000 description 3
- 150000002825 nitriles Chemical class 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 3
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 230000004850 protein–protein interaction Effects 0.000 description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 3
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- COBXDAOIDYGHGK-UHFFFAOYSA-N syringaldehyde Natural products COC1=CC=C(C=O)C(OC)=C1O COBXDAOIDYGHGK-UHFFFAOYSA-N 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- YCAAJDMLDXFLGG-DHUJRADRSA-N (2S)-1-[[4-[[3-[3-[(4-formyl-3,5-dimethoxyphenoxy)methyl]-2-methylphenyl]-2-methylphenyl]methoxy]-2,6-dimethoxyphenyl]methyl]piperidine-2-carboxylic acid Chemical compound C(=O)C1=C(C=C(OCC=2C(=C(C=CC=2)C2=C(C(=CC=C2)COC2=CC(=C(CN3[C@@H](CCCC3)C(=O)O)C(=C2)OC)OC)C)C)C=C1OC)OC YCAAJDMLDXFLGG-DHUJRADRSA-N 0.000 description 2
- ALTLCJHSJMGSLT-UHFFFAOYSA-N (3-methoxycarbonylphenyl)boronic acid Chemical compound COC(=O)C1=CC=CC(B(O)O)=C1 ALTLCJHSJMGSLT-UHFFFAOYSA-N 0.000 description 2
- RBOBOTATYFMHMJ-UHFFFAOYSA-N (4-bromo-3-methylthiophen-2-yl)methanol Chemical compound CC=1C(Br)=CSC=1CO RBOBOTATYFMHMJ-UHFFFAOYSA-N 0.000 description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- UJABRUUNNIQMBY-UHFFFAOYSA-N 2-(bromomethyl)-6-[3-(bromomethyl)phenyl]benzonitrile Chemical compound C1=CC(=CC(=C1)C2=CC=CC(=C2C#N)CBr)CBr UJABRUUNNIQMBY-UHFFFAOYSA-N 0.000 description 2
- BXGYYDRIMBPOMN-UHFFFAOYSA-N 2-(hydroxymethoxy)ethoxymethanol Chemical compound OCOCCOCO BXGYYDRIMBPOMN-UHFFFAOYSA-N 0.000 description 2
- ZQNWTEIYPKMVTC-UHFFFAOYSA-N 2-[3-[[tert-butyl(dimethyl)silyl]oxymethyl]phenyl]-6-(hydroxymethyl)benzonitrile Chemical compound CC(C)(C)[Si](C)(C)OCC1=CC(=CC=C1)C2=CC=CC(=C2C#N)CO ZQNWTEIYPKMVTC-UHFFFAOYSA-N 0.000 description 2
- OGFVUCANOAVXBK-UHFFFAOYSA-N 2-[3-[[tert-butyl(dimethyl)silyl]oxymethyl]phenyl]-6-[(2-chloro-4-formyl-5-hydroxyphenoxy)methyl]benzonitrile Chemical compound CC(C)(C)[Si](C)(C)OCC1=CC(=CC=C1)C2=CC=CC(=C2C#N)COC3=C(C=C(C(=C3)O)C=O)Cl OGFVUCANOAVXBK-UHFFFAOYSA-N 0.000 description 2
- MHVLKSPIQLHOME-UHFFFAOYSA-N 2-[5-[(2-hydroxyethylamino)methyl]-1,3-benzoxazol-2-yl]-6-[3-[[4-[(2-hydroxyethylamino)methyl]-2-methylphenoxy]methyl]phenyl]benzonitrile Chemical compound CC1=C(OCC2=CC=CC(=C2)C2=C(C#N)C(=CC=C2)C2=NC3=C(O2)C=CC(CNCCO)=C3)C=CC(CNCCO)=C1 MHVLKSPIQLHOME-UHFFFAOYSA-N 0.000 description 2
- FXUXIJPVGDMWKS-UHFFFAOYSA-N 2-[[4-(azetidin-1-ylmethyl)-2-methylphenoxy]methyl]-6-(hydroxymethyl)benzonitrile Chemical compound N1(CCC1)CC1=CC(=C(OCC2=C(C#N)C(=CC=C2)CO)C=C1)C FXUXIJPVGDMWKS-UHFFFAOYSA-N 0.000 description 2
- DGKUOJPHOADAHF-UHFFFAOYSA-N 2-[[5-[(2-hydroxyethylamino)methyl]-6-methoxypyridin-2-yl]oxymethyl]-6-[3-[[5-[(2-hydroxyethylamino)methyl]-6-methoxypyridin-2-yl]oxymethyl]phenyl]benzonitrile Chemical compound OCCNCC=1C=CC(=NC=1OC)OCC1=C(C(=CC=C1)C1=CC(=CC=C1)COC1=NC(=C(C=C1)CNCCO)OC)C#N DGKUOJPHOADAHF-UHFFFAOYSA-N 0.000 description 2
- FICQFRCPSFCFBY-UHFFFAOYSA-N 2-[bis(methylsulfanyl)methylidene]propanedinitrile Chemical compound CSC(SC)=C(C#N)C#N FICQFRCPSFCFBY-UHFFFAOYSA-N 0.000 description 2
- HHJJEPKLXMKELN-UHFFFAOYSA-N 2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide Chemical compound CC1=C(C=CC=C1B1OC(C(O1)(C)C)(C)C)S(=O)(=O)N HHJJEPKLXMKELN-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- OAVYBHNXXGWEFB-UHFFFAOYSA-N 4-[[1-[(4-formylphenyl)methyl]indol-4-yl]methoxy]-2,6-dimethoxybenzaldehyde Chemical compound C(=O)C1=CC=C(CN2C=CC3=C(C=CC=C23)COC2=CC(=C(C=O)C(=C2)OC)OC)C=C1 OAVYBHNXXGWEFB-UHFFFAOYSA-N 0.000 description 2
- VLICHVYOLACPQN-UHFFFAOYSA-N 4-[[3-[3-[(4-formyl-3,5-dimethoxyphenoxy)methyl]-2-methylphenyl]-2-methylphenyl]methoxy]-2,6-dimethoxybenzaldehyde Chemical compound CC1=C(C=CC=C1COC1=CC(=C(C=O)C(=C1)OC)OC)C1=C(C(=CC=C1)COC1=CC(=C(C=O)C(=C1)OC)OC)C VLICHVYOLACPQN-UHFFFAOYSA-N 0.000 description 2
- IPPSTGHGKWIARJ-UHFFFAOYSA-N 4-[[3-[3-[(4-formyl-5-hydroxy-2-methylphenoxy)methyl]-2-methylphenyl]-2-methylphenyl]methoxy]-2-hydroxy-5-methylbenzaldehyde Chemical compound Cc1cc(C=O)c(O)cc1OCc1cccc(c1C)-c1cccc(COc2cc(O)c(C=O)cc2C)c1C IPPSTGHGKWIARJ-UHFFFAOYSA-N 0.000 description 2
- AXGXCIXKKLSNLW-UHFFFAOYSA-N 4-[[3-[3-[[4-[(3-hydroxyazetidin-1-yl)methyl]-3-methoxyphenoxy]methyl]-2-methylphenyl]-2-methylphenyl]methoxy]benzaldehyde Chemical compound OC1CN(C1)CC1=C(C=C(OCC=2C(=C(C=CC=2)C2=C(C(=CC=C2)COC2=CC=C(C=O)C=C2)C)C)C=C1)OC AXGXCIXKKLSNLW-UHFFFAOYSA-N 0.000 description 2
- QNALMGJUOLUEMM-UHFFFAOYSA-N 4-[[3-[[4-(azetidin-1-ylmethyl)-2-methylphenoxy]methyl]-2-chlorophenyl]methoxy]-3-methylbenzaldehyde Chemical compound N1(CCC1)CC1=CC(=C(OCC=2C(=C(COC3=C(C=C(C=O)C=C3)C)C=CC=2)Cl)C=C1)C QNALMGJUOLUEMM-UHFFFAOYSA-N 0.000 description 2
- XPPUCEQTXQPRTF-UHFFFAOYSA-N 4-[[5-[(4-formyl-3-methoxyphenoxy)methyl]-4-methylthiophen-3-yl]methoxy]-2-methoxybenzaldehyde Chemical compound C(=O)C1=C(C=C(OCC=2C(=C(SC=2)COC2=CC(=C(C=O)C=C2)OC)C)C=C1)OC XPPUCEQTXQPRTF-UHFFFAOYSA-N 0.000 description 2
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 2
- XHUTYLPZWIBCIZ-UHFFFAOYSA-N 5-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=CN=CC(C#N)=C1 XHUTYLPZWIBCIZ-UHFFFAOYSA-N 0.000 description 2
- UAIGDDOKNHEVAU-UHFFFAOYSA-N 5-[[4-chloro-5-[[2-cyano-3-[3-(hydroxymethyl)phenyl]phenyl]methoxy]-2-formylphenoxy]methyl]pyridine-3-carbonitrile Chemical compound OCC1=CC=CC(=C1)C1=C(C#N)C(COC2=CC(OCC3=CN=CC(=C3)C#N)=C(C=O)C=C2Cl)=CC=C1 UAIGDDOKNHEVAU-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 2
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 206010061309 Neoplasm progression Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Chemical compound OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- LRTHZQDNOROQLW-UHFFFAOYSA-N [2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methanol Chemical compound CC1=C(CO)C=CC=C1B1OC(C)(C)C(C)(C)O1 LRTHZQDNOROQLW-UHFFFAOYSA-N 0.000 description 2
- UZORMNCRBQYYDG-UHFFFAOYSA-N [3-[3-(hydroxymethyl)-2-methylphenyl]phenyl]methanol Chemical compound CC1=C(C=CC=C1CO)C1=CC(=CC=C1)CO UZORMNCRBQYYDG-UHFFFAOYSA-N 0.000 description 2
- PUOCKKZSAZMBRZ-UHFFFAOYSA-N [3-[5-(hydroxymethyl)-4-methylthiophen-3-yl]-2-methylphenyl]methanol Chemical compound OCC=1C(=C(C=CC=1)C=1C(=C(SC=1)CO)C)C PUOCKKZSAZMBRZ-UHFFFAOYSA-N 0.000 description 2
- PIECHRVKIZGAQZ-UHFFFAOYSA-N [5-(hydroxymethyl)-4-methylthiophen-3-yl]methanol Chemical compound CC=1C(CO)=CSC=1CO PIECHRVKIZGAQZ-UHFFFAOYSA-N 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000003782 apoptosis assay Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 description 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 238000002619 cancer immunotherapy Methods 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000003709 fluoroalkyl group Chemical group 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 210000001503 joint Anatomy 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- QIGLSNKENBQQCU-UHFFFAOYSA-N methyl 2-cyano-3-(3-methoxycarbonylphenyl)benzoate Chemical compound COC(=O)c1cccc(c1)-c1cccc(C(=O)OC)c1C#N QIGLSNKENBQQCU-UHFFFAOYSA-N 0.000 description 2
- MQHHLUHBNUQXJS-UHFFFAOYSA-N methyl 3-(3-methoxycarbonyl-2-methylphenyl)-2-methylbenzoate Chemical compound COC(=O)C1=CC=CC(C=2C(=C(C(=O)OC)C=CC=2)C)=C1C MQHHLUHBNUQXJS-UHFFFAOYSA-N 0.000 description 2
- NOPHEZAEZUJUKG-UHFFFAOYSA-N methyl 3-(3-methoxycarbonylphenyl)-2-methylbenzoate Chemical compound CC1=C(C=CC=C1C(=O)OC)C2=CC(=CC=C2)C(=O)OC NOPHEZAEZUJUKG-UHFFFAOYSA-N 0.000 description 2
- HNWSLONNCMGAJD-UHFFFAOYSA-N methyl 3-[[4-(azetidin-1-ylmethyl)-2-methylphenoxy]methyl]-2-cyanobenzoate Chemical compound N1(CCC1)CC1=CC(=C(OCC=2C(=C(C(=O)OC)C=CC=2)C#N)C=C1)C HNWSLONNCMGAJD-UHFFFAOYSA-N 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000005522 programmed cell death Effects 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000005751 tumor progression Effects 0.000 description 2
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 2
- KEEKMOIRJUWKNK-CABZTGNLSA-N (2S)-2-[[2-[(4R)-4-(difluoromethyl)-2-oxo-1,3-thiazolidin-3-yl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]amino]propanamide Chemical compound FC([C@H]1N(C(SC1)=O)C=1N=C2N(CCOC3=C2C=CC(=C3)N[C@H](C(=O)N)C)C=1)F KEEKMOIRJUWKNK-CABZTGNLSA-N 0.000 description 1
- XYDXDWXAAQXHLK-UHFFFAOYSA-N (3-bromo-2-methylphenyl)methanol Chemical compound CC1=C(Br)C=CC=C1CO XYDXDWXAAQXHLK-UHFFFAOYSA-N 0.000 description 1
- SVZNSFYYVVBXOU-LQFQNGICSA-N (3R)-1-[[4-[[3-[3-[[4-[[(3R)-3-hydroxypyrrolidin-1-yl]methyl]-2-methylphenoxy]methyl]-2-methylphenyl]-2-methylphenyl]methoxy]-3-methylphenyl]methyl]pyrrolidin-3-ol Chemical compound O[C@H]1CN(CC1)CC1=CC(=C(OCC=2C(=C(C=CC=2)C2=C(C(=CC=C2)COC2=C(C=C(C=C2)CN2C[C@@H](CC2)O)C)C)C)C=C1)C SVZNSFYYVVBXOU-LQFQNGICSA-N 0.000 description 1
- NYNZQNWKBKUAII-KBXCAEBGSA-N (3s)-n-[5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypyrrolidine-1-carboxamide Chemical compound C1[C@@H](O)CCN1C(=O)NC1=C2N=C(N3[C@H](CCC3)C=3C(=CC=C(F)C=3)F)C=CN2N=C1 NYNZQNWKBKUAII-KBXCAEBGSA-N 0.000 description 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- NCWDBNBNYVVARF-UHFFFAOYSA-N 1,3,2-dioxaborolane Chemical compound B1OCCO1 NCWDBNBNYVVARF-UHFFFAOYSA-N 0.000 description 1
- YHSHGVABTKZEKC-UHFFFAOYSA-N 1,3-bis(bromomethyl)-2-chlorobenzene Chemical compound ClC1=C(CBr)C=CC=C1CBr YHSHGVABTKZEKC-UHFFFAOYSA-N 0.000 description 1
- PURSZYWBIQIANP-UHFFFAOYSA-N 1-(bromomethyl)-2-chlorobenzene Chemical compound ClC1=CC=CC=C1CBr PURSZYWBIQIANP-UHFFFAOYSA-N 0.000 description 1
- WLJPRZPZMLZZPE-UHFFFAOYSA-N 1-(bromomethyl)-3-[2-(bromomethyl)-1-methylcyclohexa-2,4-dien-1-yl]-2-methylbenzene Chemical group CC1=C(C=CC=C1C2(CC=CC=C2CBr)C)CBr WLJPRZPZMLZZPE-UHFFFAOYSA-N 0.000 description 1
- UXTOLZMJYQKSGA-UHFFFAOYSA-N 1-(bromomethyl)-3-[3-(bromomethyl)phenyl]-2-methylbenzene Chemical group CC1=C(C=CC=C1CBr)C1=CC(CBr)=CC=C1 UXTOLZMJYQKSGA-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- KJNLUXAYZKXPRD-UHFFFAOYSA-N 1-[[4-[[3-[3-[[4-[(2-hydroxyethylamino)methyl]phenoxy]methyl]-2-methylphenyl]-2-methylphenyl]methoxy]-2-methoxyphenyl]methyl]azetidin-3-ol Chemical compound COC1=C(CN2CC(O)C2)C=CC(OCC2=CC=CC(=C2C)C2=C(C)C(COC3=CC=C(CNCCO)C=C3)=CC=C2)=C1 KJNLUXAYZKXPRD-UHFFFAOYSA-N 0.000 description 1
- MICMHFIQSAMEJG-UHFFFAOYSA-N 1-bromopyrrolidine-2,5-dione Chemical compound BrN1C(=O)CCC1=O.BrN1C(=O)CCC1=O MICMHFIQSAMEJG-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- LOOWJTAKSUNLSR-UHFFFAOYSA-N 1h-indazol-4-ylmethanol Chemical compound OCC1=CC=CC2=C1C=NN2 LOOWJTAKSUNLSR-UHFFFAOYSA-N 0.000 description 1
- BVSGXWCTWBZFEV-UHFFFAOYSA-N 1h-indol-4-ylmethanol Chemical compound OCC1=CC=CC2=C1C=CN2 BVSGXWCTWBZFEV-UHFFFAOYSA-N 0.000 description 1
- JATWPRIBCRVOHC-UHFFFAOYSA-N 2,4-dihydroxy-5-methylbenzaldehyde Chemical compound CC1=CC(C=O)=C(O)C=C1O JATWPRIBCRVOHC-UHFFFAOYSA-N 0.000 description 1
- JLKTYKHHQAURMP-UHFFFAOYSA-N 2-[(4-formyl-3,5-dimethoxyphenoxy)methyl]-6-[3-[(4-formyl-3,5-dimethoxyphenoxy)methyl]phenyl]benzonitrile Chemical compound COC1=CC(=CC(=C1C=O)OC)OCC2=CC(=CC=C2)C3=CC=CC(=C3C#N)COC4=CC(=C(C(=C4)OC)C=O)OC JLKTYKHHQAURMP-UHFFFAOYSA-N 0.000 description 1
- UESWLPKZKLGUQC-UHFFFAOYSA-N 2-[(5-formyl-6-methoxypyridin-2-yl)oxymethyl]-6-[3-[(5-formyl-6-methoxypyridin-2-yl)oxymethyl]phenyl]benzonitrile Chemical compound COc1nc(OCc2cccc(c2)-c2cccc(COc3ccc(C=O)c(OC)n3)c2C#N)ccc1C=O UESWLPKZKLGUQC-UHFFFAOYSA-N 0.000 description 1
- ZSDGHWLLLGYAJV-AHEHSYJASA-N 2-[(E)-[(E)-3-[1-(2-nitrophenyl)pyrrol-2-yl]prop-2-enylidene]amino]guanidine Chemical compound NC(N)=N\N=C\C=C\C1=CC=CN1C1=CC=CC=C1[N+]([O-])=O ZSDGHWLLLGYAJV-AHEHSYJASA-N 0.000 description 1
- SSORSZACHCNXSJ-UHFFFAOYSA-N 2-[2-(3,4-dichlorophenyl)-3-[2-(2-hydroxypropylamino)pyrimidin-4-yl]imidazol-4-yl]acetonitrile Chemical compound ClC=1C=C(C=CC=1Cl)C=1N(C(=CN=1)CC#N)C1=NC(=NC=C1)NCC(C)O SSORSZACHCNXSJ-UHFFFAOYSA-N 0.000 description 1
- IYQKPDLULQZTOS-UHFFFAOYSA-N 2-[2-cyano-3-[6-[(2-hydroxyethylamino)methyl]-1,3-benzoxazol-2-yl]phenyl]-6-[6-[(2-hydroxyethylamino)methyl]-1,3-benzoxazol-2-yl]benzonitrile Chemical compound OCCNCc1ccc2nc(oc2c1)-c1cccc(-c2cccc(-c3nc4ccc(CNCCO)cc4o3)c2C#N)c1C#N IYQKPDLULQZTOS-UHFFFAOYSA-N 0.000 description 1
- IGMDLDOCPXBJND-UHFFFAOYSA-N 2-[2-cyano-3-[6-[(2-hydroxyethylamino)methyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]phenyl]-6-[6-[(2-hydroxyethylamino)methyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]benzonitrile Chemical compound OCCNCC1=CN2N=C(N=C2C=C1)C1=CC=CC(C2=C(C#N)C(=CC=C2)C2=NN3C=C(CNCCO)C=CC3=N2)=C1C#N IGMDLDOCPXBJND-UHFFFAOYSA-N 0.000 description 1
- QVEWCCZTEZPABH-UHFFFAOYSA-N 2-[2-cyano-3-[[5-[(2-hydroxyethylamino)methyl]pyridin-2-yl]oxymethyl]phenyl]-6-[[5-[(2-hydroxyethylamino)methyl]pyridin-2-yl]oxymethyl]benzonitrile Chemical compound OCCNCC=1C=CC(=NC1)OCC1=C(C(=CC=C1)C=1C(=C(C=CC1)COC1=NC=C(C=C1)CNCCO)C#N)C#N QVEWCCZTEZPABH-UHFFFAOYSA-N 0.000 description 1
- LAXZWFKGKGFIBG-UHFFFAOYSA-N 2-[4-chloro-6-[(2-hydroxyethylamino)methyl]-1,3-benzoxazol-2-yl]-6-[3-[[4-[(2-hydroxyethylamino)methyl]-2-methylphenoxy]methyl]phenyl]benzonitrile Chemical compound Cc1cc(CNCCO)ccc1OCc1cccc(c1)-c1cccc(-c2nc3c(Cl)cc(CNCCO)cc3o2)c1C#N LAXZWFKGKGFIBG-UHFFFAOYSA-N 0.000 description 1
- HSYOOAVNJFUFOA-UHFFFAOYSA-N 2-[5-[(2-hydroxyethylamino)methyl]-1,3-benzoxazol-2-yl]-6-[3-[[4-[(2-hydroxyethylamino)methyl]-3,5-dimethoxyphenoxy]methyl]phenyl]benzonitrile Chemical compound COc1cc(OCc2cccc(c2)-c2cccc(-c3nc4cc(CNCCO)ccc4o3)c2C#N)cc(OC)c1CNCCO HSYOOAVNJFUFOA-UHFFFAOYSA-N 0.000 description 1
- PRFHTHOWADGAHD-UHFFFAOYSA-N 2-[[2-[3-[3-[5-[(2-hydroxyethylamino)methyl]-1,3-dihydroisoindol-2-yl]-2-methylphenyl]-2-methylphenyl]-1,3-dihydroisoindol-5-yl]methylamino]ethanol Chemical compound Cc1c(cccc1-c1cccc(N2Cc3ccc(CNCCO)cc3C2)c1C)N1Cc2ccc(CNCCO)cc2C1 PRFHTHOWADGAHD-UHFFFAOYSA-N 0.000 description 1
- LBTDECVHDUUAQQ-UHFFFAOYSA-N 2-[[2-[3-[3-[5-[(2-hydroxyethylamino)methyl]indazol-2-yl]-2-methylphenyl]-2-methylphenyl]indazol-5-yl]methylamino]ethanol Chemical compound OCCNCC1=CC2=CN(N=C2C=C1)C=1C(=C(C=CC=1)C1=C(C(=CC=C1)N1N=C2C=CC(=CC2=C1)CNCCO)C)C LBTDECVHDUUAQQ-UHFFFAOYSA-N 0.000 description 1
- GJLYNQATOWTSQF-UHFFFAOYSA-N 2-[[2-[3-[3-[6-[(2-hydroxyethylamino)methyl]-1,3-benzoxazol-2-yl]-2-methylphenyl]-2-methylphenyl]-1,3-benzoxazol-6-yl]methylamino]ethanol Chemical compound Cc1c(cccc1-c1cccc(-c2nc3ccc(CNCCO)cc3o2)c1C)-c1nc2ccc(CNCCO)cc2o1 GJLYNQATOWTSQF-UHFFFAOYSA-N 0.000 description 1
- GJPJZXDIJPHRQE-UHFFFAOYSA-N 2-[[2-[3-[3-[6-[(2-hydroxyethylamino)methyl]imidazo[1,2-a]pyridin-2-yl]-2-methylphenyl]-2-methylphenyl]imidazo[1,2-a]pyridin-6-yl]methylamino]ethanol Chemical compound CC1=C(C=CC=C1C1=CN2C=C(CNCCO)C=CC2=N1)C1=C(C)C(=CC=C1)C1=CN2C=C(CNCCO)C=CC2=N1 GJPJZXDIJPHRQE-UHFFFAOYSA-N 0.000 description 1
- NJJWWMITEZASSO-UHFFFAOYSA-N 2-[[2-[3-[3-[6-[(2-hydroxyethylamino)methyl]imidazo[1,2-b]pyridazin-2-yl]-2-methylphenyl]-2-methylphenyl]imidazo[1,2-b]pyridazin-6-yl]methylamino]ethanol Chemical compound Cc1c(cccc1-c1cccc(-c2cn3nc(CNCCO)ccc3n2)c1C)-c1cn2nc(CNCCO)ccc2n1 NJJWWMITEZASSO-UHFFFAOYSA-N 0.000 description 1
- FKOYHVMZXGGOSG-UHFFFAOYSA-N 2-[[3-[6-[2-[3-[(2-hydroxyethylamino)methyl]phenyl]-7-methyl-1,3-benzoxazol-6-yl]-7-methyl-1,3-benzoxazol-2-yl]phenyl]methylamino]ethanol Chemical compound Cc1c(ccc2nc(oc12)-c1cccc(CNCCO)c1)-c1ccc2nc(oc2c1C)-c1cccc(CNCCO)c1 FKOYHVMZXGGOSG-UHFFFAOYSA-N 0.000 description 1
- KEGPTIRAQWBOMN-UHFFFAOYSA-N 2-[[3-[6-[3-[[4-[(2-hydroxyethylamino)methyl]-2-methylphenoxy]methyl]-2-methylphenyl]-7-methyl-1,3-benzoxazol-2-yl]phenyl]methylamino]ethanol Chemical compound Cc1cc(CNCCO)ccc1OCc1cccc(c1C)-c1ccc2nc(oc2c1C)-c1cccc(CNCCO)c1 KEGPTIRAQWBOMN-UHFFFAOYSA-N 0.000 description 1
- SPYXPVJZIOMUNI-UHFFFAOYSA-N 2-[[4-(azetidin-1-ylmethyl)-2-methylphenoxy]methyl]-6-[(4-formylphenoxy)methyl]benzonitrile Chemical compound N1(CCC1)CC1=CC(=C(OCC2=C(C#N)C(=CC=C2)COC2=CC=C(C=C2)C=O)C=C1)C SPYXPVJZIOMUNI-UHFFFAOYSA-N 0.000 description 1
- LRPIRKPSRKUGFL-UHFFFAOYSA-N 2-[[4-[(2-hydroxyethylamino)methyl]-2-methylphenoxy]methyl]-6-[3-[[4-[(2-hydroxyethylamino)methyl]-2-methylphenoxy]methyl]phenyl]benzonitrile Chemical compound Cc1cc(CNCCO)ccc1OCc1cccc(c1)-c1cccc(COc2ccc(CNCCO)cc2C)c1C#N LRPIRKPSRKUGFL-UHFFFAOYSA-N 0.000 description 1
- HOMRESKLTLTEOM-UHFFFAOYSA-N 2-[[4-[(3-hydroxyazetidin-1-yl)methyl]-3,5-dimethoxyphenoxy]methyl]-6-[3-[[4-[(3-hydroxyazetidin-1-yl)methyl]-3,5-dimethoxyphenoxy]methyl]phenyl]benzonitrile Chemical compound COc1cc(OCc2cccc(c2)-c2cccc(COc3cc(OC)c(CN4CC(O)C4)c(OC)c3)c2C#N)cc(OC)c1CN1CC(O)C1 HOMRESKLTLTEOM-UHFFFAOYSA-N 0.000 description 1
- JZJLFNMKVUPIKH-UHFFFAOYSA-N 2-[[4-[6-[2-[4-[(2-hydroxyethylamino)methyl]phenyl]-7-methyl-1,3-benzoxazol-6-yl]-7-methyl-1,3-benzoxazol-2-yl]phenyl]methylamino]ethanol Chemical compound Cc1c(ccc2nc(oc12)-c1ccc(CNCCO)cc1)-c1ccc2nc(oc2c1C)-c1ccc(CNCCO)cc1 JZJLFNMKVUPIKH-UHFFFAOYSA-N 0.000 description 1
- RMJKBGOPLKPOPZ-UHFFFAOYSA-N 2-[[4-[[2-[3-[[4-[(2-hydroxyethylamino)methyl]-2-methylphenoxy]methyl]-2-methylphenyl]pyridin-4-yl]methoxy]-3-methylphenyl]methylamino]ethanol Chemical compound OCCNCC1=CC(=C(OCC=2C(=C(C=CC=2)C2=NC=CC(=C2)COC2=C(C=C(C=C2)CNCCO)C)C)C=C1)C RMJKBGOPLKPOPZ-UHFFFAOYSA-N 0.000 description 1
- QJGWELBRVFNNKE-UHFFFAOYSA-N 2-[[4-[[2-[3-[[4-[(2-hydroxyethylamino)methyl]-3,5-dimethoxyphenoxy]methyl]-2-methylphenyl]pyridin-4-yl]methoxy]-2,6-dimethoxyphenyl]methylamino]ethanol Chemical compound OCCNCC1=C(C=C(OCC=2C(=C(C=CC=2)C2=NC=CC(=C2)COC2=CC(=C(C(=C2)OC)CNCCO)OC)C)C=C1OC)OC QJGWELBRVFNNKE-UHFFFAOYSA-N 0.000 description 1
- VXYCUMQATLLYAL-UHFFFAOYSA-N 2-[[4-[[3-[3-[4-chloro-6-[(2-hydroxyethylamino)methyl]-1,3-benzoxazol-2-yl]-2-methylphenyl]-2-methylphenyl]methoxy]-3-methylphenyl]methylamino]ethanol Chemical compound ClC1=CC(=CC2=C1N=C(O2)C=1C(=C(C=CC=1)C1=C(C(=CC=C1)COC1=C(C=C(C=C1)CNCCO)C)C)C)CNCCO VXYCUMQATLLYAL-UHFFFAOYSA-N 0.000 description 1
- BLKCCKQSDKRPAM-UHFFFAOYSA-N 2-[[4-[[3-[3-[5-[(2-hydroxyethylamino)methyl]-1,3-benzothiazol-2-yl]-2-methylphenyl]-2-methylphenyl]methoxy]-3-methylphenyl]methylamino]ethanol Chemical compound Cc1cc(CNCCO)ccc1OCc1cccc(c1C)-c1cccc(-c2nc3cc(CNCCO)ccc3s2)c1C BLKCCKQSDKRPAM-UHFFFAOYSA-N 0.000 description 1
- POXAZSRRMICYGH-UHFFFAOYSA-N 2-[[4-[[3-[3-[5-[(2-hydroxyethylamino)methyl]-1,3-benzoxazol-2-yl]-2-methylphenyl]-2-methylphenyl]methoxy]-3-methylphenyl]methylamino]ethanol Chemical compound Cc1cc(CNCCO)ccc1OCc1cccc(c1C)-c1cccc(-c2nc3cc(CNCCO)ccc3o2)c1C POXAZSRRMICYGH-UHFFFAOYSA-N 0.000 description 1
- FTDYWEJUDRAJHS-UHFFFAOYSA-N 2-[[4-[[3-[3-[6-[(2-hydroxyethylamino)methyl]-1,3-benzothiazol-2-yl]-2-methylphenyl]-2-methylphenyl]methoxy]-3-methylphenyl]methylamino]ethanol Chemical compound Cc1cc(CNCCO)ccc1OCc1cccc(c1C)-c1cccc(-c2nc3ccc(CNCCO)cc3s2)c1C FTDYWEJUDRAJHS-UHFFFAOYSA-N 0.000 description 1
- BSGWWXFQQFBNJX-UHFFFAOYSA-N 2-[[4-[[3-[3-[6-[(2-hydroxyethylamino)methyl]-1,3-benzoxazol-2-yl]-2-methylphenyl]-2-methylphenyl]methoxy]-3-methylphenyl]methylamino]ethanol Chemical compound Cc1cc(CNCCO)ccc1OCc1cccc(c1C)-c1cccc(-c2nc3ccc(CNCCO)cc3o2)c1C BSGWWXFQQFBNJX-UHFFFAOYSA-N 0.000 description 1
- ZGMPPJPQWFQTNE-UHFFFAOYSA-N 2-[[4-[[3-[5-[[4-[(2-hydroxyethylamino)methyl]-2-methylphenoxy]methyl]-4-methylthiophen-3-yl]-2-methylphenyl]methoxy]-3-methylphenyl]methylamino]ethanol Chemical compound OCCNCC1=CC(=C(OCC=2C(=C(C=CC=2)C=2C(=C(SC=2)COC2=C(C=C(C=C2)CNCCO)C)C)C)C=C1)C ZGMPPJPQWFQTNE-UHFFFAOYSA-N 0.000 description 1
- FOTYYHLRDULPGY-UHFFFAOYSA-N 2-[[4-[[3-[6-[[4-[(2-hydroxyethylamino)methyl]-3,5-dimethoxyphenoxy]methyl]pyridin-2-yl]-2-methylphenyl]methoxy]-2,6-dimethoxyphenyl]methylamino]ethanol Chemical compound OCCNCC1=C(C=C(OCC=2C(=C(C=CC=2)C2=CC=CC(=N2)COC2=CC(=C(C(=C2)OC)CNCCO)OC)C)C=C1OC)OC FOTYYHLRDULPGY-UHFFFAOYSA-N 0.000 description 1
- GQNHWXVCWCDDPP-UHFFFAOYSA-N 2-[[4-[[4-[5-[[4-[(2-hydroxyethylamino)methyl]-2-methylphenoxy]methyl]-4-methylthiophen-3-yl]-3-methylthiophen-2-yl]methoxy]-3-methylphenyl]methylamino]ethanol Chemical compound OCCNCC1=CC(=C(OCC2=C(C(=CS2)C2=CSC(=C2C)COC2=C(C=C(C=C2)CNCCO)C)C)C=C1)C GQNHWXVCWCDDPP-UHFFFAOYSA-N 0.000 description 1
- UUMCOHZWIHZGHN-UHFFFAOYSA-N 2-[[5-[(2-hydroxyethylamino)methyl]pyridin-2-yl]oxymethyl]-6-[3-[[5-[(2-hydroxyethylamino)methyl]pyridin-2-yl]oxymethyl]phenyl]benzonitrile Chemical compound OCCNCC=1C=CC(=NC1)OCC1=C(C(=CC=C1)C1=CC(=CC=C1)COC1=NC=C(C=C1)CNCCO)C#N UUMCOHZWIHZGHN-UHFFFAOYSA-N 0.000 description 1
- CNQBXNRWBKMRQE-UHFFFAOYSA-N 2-[[6-[[3-[3-[[5-[(2-hydroxyethylamino)methyl]pyridin-2-yl]oxymethyl]-2-methylphenyl]-2-methylphenyl]methoxy]pyridin-3-yl]methylamino]ethanol Chemical compound OCCNCC=1C=CC(=NC=1)OCC=1C(=C(C=CC=1)C1=C(C(=CC=C1)COC1=CC=C(C=N1)CNCCO)C)C CNQBXNRWBKMRQE-UHFFFAOYSA-N 0.000 description 1
- JMAWZVCZLOEOCE-UHFFFAOYSA-N 2-bromo-6-(hydroxymethyl)benzonitrile Chemical compound BrC1=C(C#N)C(=CC=C1)CO JMAWZVCZLOEOCE-UHFFFAOYSA-N 0.000 description 1
- VDXLAYAQGYCQEO-UHFFFAOYSA-N 2-chloro-1,3-dimethylbenzene Chemical compound CC1=CC=CC(C)=C1Cl VDXLAYAQGYCQEO-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- UBKKNWJGYLSDSJ-UHFFFAOYSA-N 2-methylpyridine-3-carbonitrile Chemical compound CC1=NC=CC=C1C#N UBKKNWJGYLSDSJ-UHFFFAOYSA-N 0.000 description 1
- TWBPWBPGNQWFSJ-UHFFFAOYSA-N 2-phenylaniline Chemical group NC1=CC=CC=C1C1=CC=CC=C1 TWBPWBPGNQWFSJ-UHFFFAOYSA-N 0.000 description 1
- BJGKVCKGUBYULR-UHFFFAOYSA-N 3-bromo-2-methylbenzoic acid Chemical compound CC1=C(Br)C=CC=C1C(O)=O BJGKVCKGUBYULR-UHFFFAOYSA-N 0.000 description 1
- GDZHCULSVTVDMD-UHFFFAOYSA-N 3-methyl-4-[[2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methoxy]benzaldehyde Chemical compound CC1=C(OCC2=C(C)C(=CC=C2)B2OC(C)(C)C(C)(C)O2)C=CC(C=O)=C1 GDZHCULSVTVDMD-UHFFFAOYSA-N 0.000 description 1
- NZKJPJDAAYDUEZ-UHFFFAOYSA-N 4-(1H-indol-4-ylmethoxy)-2,6-dimethoxybenzaldehyde Chemical compound N1C=CC2=C(C=CC=C12)COC1=CC(=C(C=O)C(=C1)OC)OC NZKJPJDAAYDUEZ-UHFFFAOYSA-N 0.000 description 1
- UFWIEBMUQXPBCX-UHFFFAOYSA-N 4-(aminomethyl)azetidin-2-one Chemical compound NCC1CC(=O)N1 UFWIEBMUQXPBCX-UHFFFAOYSA-N 0.000 description 1
- XYPVBKDHERGKJG-UHFFFAOYSA-N 4-(bromomethyl)benzaldehyde Chemical compound BrCC1=CC=C(C=O)C=C1 XYPVBKDHERGKJG-UHFFFAOYSA-N 0.000 description 1
- AYAZHAVCLAUJLX-UHFFFAOYSA-N 4-[[3-[3-[(4-formyl-2-methylphenoxy)methyl]-2-methylphenyl]-2-methylphenyl]methoxy]-3-methylbenzaldehyde Chemical compound CC1=C(C=CC=C1COC1=C(C=C(C=O)C=C1)C)C1=C(C(=CC=C1)COC1=C(C=C(C=O)C=C1)C)C AYAZHAVCLAUJLX-UHFFFAOYSA-N 0.000 description 1
- SJPWRGKRYPMQPK-UHFFFAOYSA-N 4-[[3-[3-[[4-[(3-hydroxyazetidin-1-yl)methyl]-3-methoxyphenoxy]methyl]-2-methylphenyl]-2-methylphenyl]methoxy]-3-methylbenzaldehyde Chemical compound COc1cc(OCc2cccc(c2C)-c2cccc(COc3ccc(C=O)cc3C)c2C)ccc1CN1CC(O)C1 SJPWRGKRYPMQPK-UHFFFAOYSA-N 0.000 description 1
- JZJVKBDHCIFIHJ-UHFFFAOYSA-N 4-bromo-3-methylbenzenecarbothioic S-acid Chemical compound BrC1=C(C=C(C(=S)O)C=C1)C JZJVKBDHCIFIHJ-UHFFFAOYSA-N 0.000 description 1
- DNTZAFOJXZEFML-UHFFFAOYSA-N 5-[[3-[[3-[3-[[5-[(5-cyanopyridin-3-yl)methoxy]-2-methylphenoxy]methyl]-2-methylphenyl]-2-methylphenyl]methoxy]-4-methylphenoxy]methyl]pyridine-3-carbonitrile Chemical compound Cc1ccc(OCc2cncc(c2)C#N)cc1OCc1cccc(c1C)-c1cccc(COc2cc(OCc3cncc(c3)C#N)ccc2C)c1C DNTZAFOJXZEFML-UHFFFAOYSA-N 0.000 description 1
- RVCGVEMNNUUIRH-UHFFFAOYSA-N 5-[[4-chloro-5-[[2-cyano-3-[3-[(4-formyl-2-methylphenoxy)methyl]phenyl]phenyl]methoxy]-2-formylphenoxy]methyl]pyridine-3-carbonitrile Chemical compound CC1=C(OCC2=CC=CC(=C2)C2=C(C#N)C(COC3=CC(OCC4=CN=CC(=C4)C#N)=C(C=O)C=C3Cl)=CC=C2)C=CC(C=O)=C1 RVCGVEMNNUUIRH-UHFFFAOYSA-N 0.000 description 1
- IPOSHVWRFQTHGK-UHFFFAOYSA-N 5-chloro-2,4-dihydroxybenzaldehyde Chemical compound OC1=CC(O)=C(C=O)C=C1Cl IPOSHVWRFQTHGK-UHFFFAOYSA-N 0.000 description 1
- FTDLRWBCHXCECH-UHFFFAOYSA-N 5h-[1,3]oxazolo[4,5-d]triazole Chemical compound N1=NC2=NCOC2=N1 FTDLRWBCHXCECH-UHFFFAOYSA-N 0.000 description 1
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 1
- OHGMQDYJKSUAKD-UHFFFAOYSA-N 6-[[3-[5-[(5-formyl-6-methoxypyridin-2-yl)oxymethyl]-4-methylthiophen-3-yl]-2-methylphenyl]methoxy]-2-methoxypyridine-3-carbaldehyde Chemical compound C(=O)C=1C=CC(=NC=1OC)OCC1=C(C(=CS1)C=1C(=C(C=CC=1)COC1=CC=C(C(=N1)OC)C=O)C)C OHGMQDYJKSUAKD-UHFFFAOYSA-N 0.000 description 1
- ONPGOSVDVDPBCY-CQSZACIVSA-N 6-amino-5-[(1r)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-n-[4-(4-methylpiperazine-1-carbonyl)phenyl]pyridazine-3-carboxamide Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NN=1)N)=CC=1C(=O)NC(C=C1)=CC=C1C(=O)N1CCN(C)CC1 ONPGOSVDVDPBCY-CQSZACIVSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- IXSLKDKZXHCYEK-UHFFFAOYSA-N CC(C=C(CNCCO)C=C1)=C1OCC1=CC=CC(C2=CC(COC3=CC(OCC4=CC=CN=C4)=C(CNCCO)C=C3)=CC=C2)=C1 Chemical compound CC(C=C(CNCCO)C=C1)=C1OCC1=CC=CC(C2=CC(COC3=CC(OCC4=CC=CN=C4)=C(CNCCO)C=C3)=CC=C2)=C1 IXSLKDKZXHCYEK-UHFFFAOYSA-N 0.000 description 1
- USQOVYLRWBOSQC-HNNXBMFYSA-N CCCCCCNC(=O)Oc1cccc(c1)-c1ccc(cc1F)[C@H](C)C(O)=O Chemical compound CCCCCCNC(=O)Oc1cccc(c1)-c1ccc(cc1F)[C@H](C)C(O)=O USQOVYLRWBOSQC-HNNXBMFYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 238000006964 Chan-Lam coupling reaction Methods 0.000 description 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical class ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 1
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- 229910010084 LiAlH4 Inorganic materials 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- ZKGNPQKYVKXMGJ-UHFFFAOYSA-N N,N-dimethylacetamide Chemical compound CN(C)C(C)=O.CN(C)C(C)=O ZKGNPQKYVKXMGJ-UHFFFAOYSA-N 0.000 description 1
- 238000007126 N-alkylation reaction Methods 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 238000010934 O-alkylation reaction Methods 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 101710094000 Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 229910006074 SO2NH2 Inorganic materials 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- AJRJLXLBOYWMEC-UHFFFAOYSA-N azanium;4-(pyridin-3-ylmethylcarbamoylamino)benzenesulfinate Chemical compound [NH4+].C1=CC(S(=O)[O-])=CC=C1NC(=O)NCC1=CC=CN=C1 AJRJLXLBOYWMEC-UHFFFAOYSA-N 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- GMWFCJXSQQHBPI-UHFFFAOYSA-N azetidin-3-ol Chemical compound OC1CNC1 GMWFCJXSQQHBPI-UHFFFAOYSA-N 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000001023 centrifugal evaporation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010568 chiral column chromatography Methods 0.000 description 1
- NMMPMZWIIQCZBA-UHFFFAOYSA-M chloropalladium(1+);dicyclohexyl-[2-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane;2-phenylethanamine Chemical compound [Pd+]Cl.NCCC1=CC=CC=[C-]1.CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 NMMPMZWIIQCZBA-UHFFFAOYSA-M 0.000 description 1
- RSLSVURFMXHEEU-UHFFFAOYSA-M chloropalladium(1+);dicyclohexyl-[3-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane;2-phenylaniline Chemical compound [Pd+]Cl.NC1=CC=CC=C1C1=CC=CC=[C-]1.CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC(P(C2CCCCC2)C2CCCCC2)=C1 RSLSVURFMXHEEU-UHFFFAOYSA-M 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 125000005959 diazepanyl group Chemical group 0.000 description 1
- RSYMPAMELGIPOR-UHFFFAOYSA-N dimethyl 3-methylthiophene-2,4-dicarboxylate Chemical compound COC(=O)C1=CSC(C(=O)OC)=C1C RSYMPAMELGIPOR-UHFFFAOYSA-N 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- UZZWBUYVTBPQIV-UHFFFAOYSA-N dme dimethoxyethane Chemical compound COCCOC.COCCOC UZZWBUYVTBPQIV-UHFFFAOYSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 238000013104 docking experiment Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 102000048362 human PDCD1 Human genes 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000012304 luminex technique Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- HKIWSNQLOOLXOH-UHFFFAOYSA-N methanol;2,2,2-trifluoroacetic acid;hydrate Chemical compound O.OC.OC(=O)C(F)(F)F HKIWSNQLOOLXOH-UHFFFAOYSA-N 0.000 description 1
- QBRYNBVJRXAIRI-UHFFFAOYSA-N methyl 2-cyano-3-(hydroxymethyl)benzoate Chemical compound C(#N)C1=C(C(=O)OC)C=CC=C1CO QBRYNBVJRXAIRI-UHFFFAOYSA-N 0.000 description 1
- JTKBWUQNFHIFIW-UHFFFAOYSA-N methyl 3-bromo-2-cyanobenzoate Chemical compound COC(=O)C1=CC=CC(Br)=C1C#N JTKBWUQNFHIFIW-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- DAKZISABEDGGSV-UHFFFAOYSA-N n-(2-aminoethyl)acetamide Chemical compound CC(=O)NCCN DAKZISABEDGGSV-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 1
- 238000010651 palladium-catalyzed cross coupling reaction Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000012041 precatalyst Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- XUBCZJLUSMNFFT-UHFFFAOYSA-N tert-butyl-dimethyl-[[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methoxy]silane Chemical compound [Si](C)(C)(C(C)(C)C)OCC=1C=C(C=CC=1)B1OC(C)(C)C(C)(C)O1 XUBCZJLUSMNFFT-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- PHCBRBWANGJMHS-UHFFFAOYSA-J tetrasodium;disulfate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O PHCBRBWANGJMHS-UHFFFAOYSA-J 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000004305 thiazinyl group Chemical group S1NC(=CC=C1)* 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000001583 thiepanyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/333—Radicals substituted by oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C07D213/85—Nitriles in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
- C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
Description
Cpd ID | PD-1/PD-LI HTRF IC<sub>50</sub> |
I-1 | A |
I-2 | C |
I-3 | C |
I-4 | B |
I-5 | A |
I-6 | A |
Claims (13)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662370679P | 2016-08-03 | 2016-08-03 | |
US62/370,679 | 2016-08-03 | ||
PCT/US2017/045185 WO2018026971A1 (en) | 2016-08-03 | 2017-08-02 | Symmetric or semi-symmetric compounds useful as immunomodulators |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109195602A CN109195602A (zh) | 2019-01-11 |
CN109195602B true CN109195602B (zh) | 2022-01-07 |
Family
ID=61073835
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201780024052.4A Active CN109195602B (zh) | 2016-08-03 | 2017-08-02 | 用作免疫调节剂的对称或半对称化合物 |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP3493804A1 (zh) |
JP (1) | JP2019530732A (zh) |
CN (1) | CN109195602B (zh) |
AU (1) | AU2017305399A1 (zh) |
CA (1) | CA3030773A1 (zh) |
WO (1) | WO2018026971A1 (zh) |
Families Citing this family (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017070089A1 (en) | 2015-10-19 | 2017-04-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
EP4141002A1 (en) | 2015-11-19 | 2023-03-01 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
PL3394033T3 (pl) | 2015-12-22 | 2021-05-31 | Incyte Corporation | Związki heterocykliczne jako immunomodulatory |
TW201808950A (zh) | 2016-05-06 | 2018-03-16 | 英塞特公司 | 作為免疫調節劑之雜環化合物 |
MA45116A (fr) | 2016-05-26 | 2021-06-02 | Incyte Corp | Composés hétérocycliques comme immunomodulateurs |
MX2018016273A (es) | 2016-06-20 | 2019-07-04 | Incyte Corp | Compuestos heterociclicos como inmunomoduladores. |
EP3484866B1 (en) | 2016-07-14 | 2022-09-07 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
MA46045A (fr) | 2016-08-29 | 2021-04-28 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
US10144706B2 (en) * | 2016-09-01 | 2018-12-04 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
IL265921B1 (en) | 2016-10-14 | 2024-01-01 | Prec Biosciences Inc | Transgenic meganonucleases specific for recognition sequences in the hepatitis B virus genome |
MD3558990T2 (ro) * | 2016-12-22 | 2023-02-28 | Incyte Corp | Derivați tetrahidro imidazo[4,5-c]piridină ca inductori de internalizare a PD-L1 |
CN110582493B (zh) | 2016-12-22 | 2024-03-08 | 因赛特公司 | 作为免疫调节剂的苯并噁唑衍生物 |
ES2899402T3 (es) | 2016-12-22 | 2022-03-11 | Incyte Corp | Derivados de piridina como inmunomoduladores |
EP3558989B1 (en) | 2016-12-22 | 2021-04-14 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
WO2018200571A1 (en) | 2017-04-25 | 2018-11-01 | Arbutus Biopharma Corporation | Substituted 2,3-dihydro-1h-indene analogs and methods using same |
CN109400522B (zh) * | 2017-08-18 | 2023-04-28 | 上海轶诺药业有限公司 | 一种具有pd-l1抑制活性的化合物、其制备方法及用途 |
US11833156B2 (en) | 2017-09-22 | 2023-12-05 | Jubilant Epipad LLC | Heterocyclic compounds as pad inhibitors |
FI3697785T3 (fi) | 2017-10-18 | 2023-04-03 | Jubilant Epipad LLC | Imidatsopyridiiniyhdisteitä pad:n estäjinä |
EP3707135A1 (en) | 2017-11-06 | 2020-09-16 | Jubilant Prodel LLC | Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation |
JP7368369B2 (ja) | 2017-11-24 | 2023-10-24 | ジュビラント・エピスクライブ・エルエルシー | Prmt5阻害剤としてのヘテロ環式化合物 |
US10966999B2 (en) | 2017-12-20 | 2021-04-06 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
AU2018392212B9 (en) | 2017-12-20 | 2021-03-18 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
EP3750887A4 (en) * | 2018-02-05 | 2021-10-20 | Abbisko Therapeutics Co., Ltd. | BIARYLE DERIVATIVE, ITS PREPARATION PROCESS, AND ITS PHARMACEUTICAL APPLICATION |
UA126458C2 (uk) | 2018-02-13 | 2022-10-05 | Гіліад Сайєнсіз, Інк. | Інгібітори pd-1/pd-l1 |
EP3759109B1 (en) | 2018-02-26 | 2023-08-30 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds as hbv replication inhibitors |
JP7279063B6 (ja) * | 2018-03-13 | 2024-02-15 | ジュビラント プローデル エルエルシー | Pd1/pd-l1相互作用/活性化の阻害剤としての二環式化合物 |
WO2019191684A1 (en) | 2018-03-30 | 2019-10-03 | Incyte Corporation | Treatment of hidradenitis suppurativa using jak inhibitors |
SG11202009440WA (en) * | 2018-03-30 | 2020-10-29 | Incyte Corp | Heterocyclic compounds as immunomodulators |
JP2021520342A (ja) * | 2018-04-03 | 2021-08-19 | ベータ ファーマシューティカルズ カンパニー リミテッド | 免疫調節物質、組成物及びそれらの方法 |
US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | 2,2,─環二核苷酸 |
WO2019193543A1 (en) | 2018-04-06 | 2019-10-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides |
US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
JP7242702B2 (ja) * | 2018-04-19 | 2023-03-20 | ギリアード サイエンシーズ, インコーポレイテッド | Pd-1/pd-l1阻害剤 |
TW202014193A (zh) | 2018-05-03 | 2020-04-16 | 捷克科學院有機化學與生物化學研究所 | 包含碳環核苷酸之2’3’-環二核苷酸 |
DK3790877T3 (da) * | 2018-05-11 | 2023-04-24 | Incyte Corp | Tetrahydro-imidazo[4,5-c]pyridinderivater som pd-l1-immunmodulatorer |
WO2019232319A1 (en) | 2018-05-31 | 2019-12-05 | Peloton Therapeutics, Inc. | Compositions and methods for inhibiting cd73 |
TWI732245B (zh) | 2018-07-13 | 2021-07-01 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
WO2020011246A1 (zh) * | 2018-07-13 | 2020-01-16 | 广州丹康医药生物有限公司 | 含苯环的化合物、其制备方法及应用 |
CN110790758A (zh) * | 2018-08-01 | 2020-02-14 | 上海轶诺药业有限公司 | 一类具有免疫调节功能的含n杂环化合物的制备和应用 |
CN112638899B (zh) * | 2018-08-01 | 2023-09-05 | 上海轶诺药业有限公司 | 一类具有免疫调节功能的芳香化合物的制备和应用 |
WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
KR20210061359A (ko) * | 2018-09-13 | 2021-05-27 | 베타 파머수티컬 컴퍼니 리미티드 | 면역조절제, 그의 조성물 및 방법 |
WO2020086556A1 (en) | 2018-10-24 | 2020-04-30 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
CA3117556A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
EP3873608A1 (en) | 2018-10-31 | 2021-09-08 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
TWI827760B (zh) | 2018-12-12 | 2024-01-01 | 加拿大商愛彼特生物製藥公司 | 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法 |
EP3917927A4 (en) * | 2019-01-31 | 2022-10-26 | Betta Pharmaceuticals Co., Ltd | IMMUNE MODULATORS, COMPOSITIONS AND METHODS THEREOF |
JP7350872B2 (ja) | 2019-03-07 | 2023-09-26 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. | 3’3’-環状ジヌクレオチドおよびそのプロドラッグ |
CN113543851A (zh) | 2019-03-07 | 2021-10-22 | 捷克共和国有机化学与生物化学研究所 | 2’3’-环二核苷酸及其前药 |
WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
CN109897036B (zh) * | 2019-03-15 | 2021-07-30 | 沈阳药科大学 | 三唑并吡啶类化合物及其制备方法和用途 |
AU2020246317A1 (en) | 2019-03-22 | 2021-11-18 | Guangzhou Maxinovel Pharmaceuticals Co., Ltd | Small-molecule inhibitor of PD-1/PD-L1, pharmaceutical composition thereof with PD-L1 antibody, and application of same |
TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
CN112028870B (zh) * | 2019-06-04 | 2021-11-05 | 中国科学院上海药物研究所 | 一种具有苄氧基芳环结构的化合物,其制备方法和用途 |
US20220305114A1 (en) * | 2019-06-18 | 2022-09-29 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and small molecule pdl1 or pd1 inhibitor |
US20220257619A1 (en) | 2019-07-18 | 2022-08-18 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
WO2021030162A1 (en) | 2019-08-09 | 2021-02-18 | Incyte Corporation | Salts of a pd-1/pd-l1 inhibitor |
WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
CN114555799A (zh) | 2019-09-30 | 2022-05-27 | 吉利德科学公司 | Hbv疫苗和治疗hbv的方法 |
US11401279B2 (en) | 2019-09-30 | 2022-08-02 | Incyte Corporation | Pyrido[3,2-d]pyrimidine compounds as immunomodulators |
TW202120504A (zh) | 2019-11-11 | 2021-06-01 | 美商英塞特公司 | Pd-1/pd-l1 抑制劑之鹽及結晶型 |
EP4069729A1 (en) | 2019-12-06 | 2022-10-12 | Precision BioSciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
CN112979641A (zh) * | 2019-12-17 | 2021-06-18 | 上海轶诺药业有限公司 | 一类具有免疫调节功能的含n杂环化合物的制备和应用 |
CA3166246A1 (en) * | 2020-02-03 | 2021-08-12 | Vijay Ahuja | Substituted 1,1'-biphenyl compounds and methods using same |
CN113248492B (zh) * | 2020-02-10 | 2022-11-08 | 上海海雁医药科技有限公司 | 杂环取代的含氮六元杂环衍生物及其制法与医药上的用途 |
EP4121437A1 (en) | 2020-03-20 | 2023-01-25 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
EP4146345A2 (en) | 2020-05-05 | 2023-03-15 | Teon Therapeutics, Inc. | Cannabinoid receptor type 2 (cb2) modulators and uses thereof |
CA3182131A1 (en) | 2020-05-22 | 2021-11-25 | Aligos Therapeutics, Inc. | Methods and compositions for targeting pd-l1 |
AU2021373044A1 (en) | 2020-11-06 | 2023-06-08 | Incyte Corporation | Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof |
WO2022099018A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process of preparing a pd-1/pd-l1 inhibitor |
TW202233615A (zh) | 2020-11-06 | 2022-09-01 | 美商英塞特公司 | Pd—1/pd—l1抑制劑之結晶形式 |
WO2022147302A1 (en) * | 2020-12-30 | 2022-07-07 | Chulalongkorn University | 4-phenyl-indole derivatives and related uses |
EP4313946A1 (en) * | 2021-03-26 | 2024-02-07 | Jacobio Pharmaceuticals Co., Ltd. | Novel compounds useful as sting agonists and uses thereof |
CN113135895A (zh) * | 2021-04-30 | 2021-07-20 | 中国药科大学 | 一种新型联苯类衍生物及其制备方法与医药用途 |
WO2022241134A1 (en) | 2021-05-13 | 2022-11-17 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
CA3222269A1 (en) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-cancer agents |
WO2022261310A1 (en) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-body drug conjugates |
CN113321575B (zh) * | 2021-06-15 | 2023-05-26 | 南开大学 | 一种苄基芳基醚的制备方法及其在合成中的应用 |
US11932634B2 (en) | 2021-06-23 | 2024-03-19 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
EP4359415A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
CN117377671A (zh) | 2021-06-23 | 2024-01-09 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
TW202325306A (zh) | 2021-09-02 | 2023-07-01 | 美商天恩治療有限公司 | 改良免疫細胞之生長及功能的方法 |
WO2023081730A1 (en) | 2021-11-03 | 2023-05-11 | Teon Therapeutics, Inc. | 4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid cb2 receptor modulators for the treatment of cancer |
WO2023097211A1 (en) | 2021-11-24 | 2023-06-01 | The University Of Southern California | Methods for enhancing immune checkpoint inhibitor therapy |
WO2024015372A1 (en) | 2022-07-14 | 2024-01-18 | Teon Therapeutics, Inc. | Adenosine receptor antagonists and uses thereof |
WO2024019957A1 (en) * | 2022-07-18 | 2024-01-25 | Celgene Corporation | Compounds for the treatment of neurodegenerative diseases |
WO2024032782A1 (en) * | 2022-08-12 | 2024-02-15 | Jacobio Pharmaceuticals Co.Ltd. | Vaccine adjuvants and uses thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011082400A2 (en) * | 2010-01-04 | 2011-07-07 | President And Fellows Of Harvard College | Modulators of immunoinhibitory receptor pd-1, and methods of use thereof |
UY34616A (es) * | 2012-02-10 | 2013-09-30 | Galapagos Nv | Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias. |
WO2014066834A1 (en) * | 2012-10-26 | 2014-05-01 | The University Of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
MX2016002544A (es) * | 2013-09-04 | 2016-06-17 | Squibb Bristol Myers Co | Compuestos utiles como inmunomoduladores. |
US9850225B2 (en) * | 2014-04-14 | 2017-12-26 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
-
2017
- 2017-08-02 AU AU2017305399A patent/AU2017305399A1/en not_active Abandoned
- 2017-08-02 JP JP2019527771A patent/JP2019530732A/ja active Pending
- 2017-08-02 CA CA3030773A patent/CA3030773A1/en not_active Abandoned
- 2017-08-02 EP EP17837640.6A patent/EP3493804A1/en not_active Withdrawn
- 2017-08-02 CN CN201780024052.4A patent/CN109195602B/zh active Active
- 2017-08-02 WO PCT/US2017/045185 patent/WO2018026971A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2019530732A (ja) | 2019-10-24 |
CA3030773A1 (en) | 2018-02-08 |
EP3493804A1 (en) | 2019-06-12 |
WO2018026971A1 (en) | 2018-02-08 |
CN109195602A (zh) | 2019-01-11 |
AU2017305399A1 (en) | 2019-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109195602B (zh) | 用作免疫调节剂的对称或半对称化合物 | |
JP7005582B2 (ja) | ブルトン型チロシンキナーゼ(btk)インヒビターとしての多フルオロ置換化合物 | |
CN108349940B (zh) | 布鲁顿酪氨酸激酶抑制剂 | |
CA2953798C (en) | Aminopyridazinone compounds as protein kinase inhibitors | |
JP6955482B2 (ja) | Tnfアルファの修飾因子として有用なヘテロ環化合物 | |
KR101320763B1 (ko) | 키나아제 억제제로서의 신규 페닐피라지논 | |
TW202144345A (zh) | Kras突變蛋白抑制劑 | |
CN110494433B (zh) | 布鲁顿酪氨酸激酶抑制剂 | |
KR20200103760A (ko) | Parp14 억제제로서의 퀴나졸리논 | |
JP2023520759A (ja) | がん治療のための置換オキソイソインドリン化合物 | |
JP2024505732A (ja) | ピリドピリミジノン系誘導体及びその製造方法と使用 | |
EP2976341A1 (en) | Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors | |
JP2021505684A (ja) | ヒストンデアセチラーゼ6阻害剤としての1,2,4−オキサジアゾール誘導体 | |
CN111560012A (zh) | 一种作为irak抑制剂的化合物 | |
JP2016514709A (ja) | ヤヌスキナーゼ阻害剤としてのジェミナル置換シアノエチルピラゾロピリドン | |
CA3114259A1 (en) | Aminonorbornane derivative and manufacture method therefor and use thereof | |
WO2014157687A1 (ja) | アセトアミド基を有する1,2,4-トリアジン-6-カルボキサミド誘導体 | |
US20220125787A1 (en) | Compounds and compositions for treating conditions associated with apj receptor activity | |
KR20230016219A (ko) | Il-17a 조절제 | |
CN107849044B (zh) | 作为ddr1抑制剂的三氮杂-螺癸酮类化合物 | |
CA2893637A1 (en) | Thiazole derivatives as inhibitors of bruton's tyrosine kinase | |
JP2024516194A (ja) | Pd1/pd-l1阻害剤としての化合物及びその方法 | |
WO2022117090A1 (zh) | 一种多环化合物及其制备方法和用途 | |
WO2020233645A1 (zh) | 大环类衍生物、及其制备方法和用途 | |
CN115768757A (zh) | Cd206调节剂及其用途和制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20200825 Address after: Xinluo Avenue high tech Zone of Ji'nan City, Shandong Province, No. 317 250101 Applicant after: Qilu Pharmaceutical Co.,Ltd. Address before: Massachusetts, USA Applicant before: ARISING INTERNATIONAL, LLC Applicant before: Qilu Pharmaceutical Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20211203 Address after: 201203 Building 1, No. 576, libing Road, No. 56, Faraday Road, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai Applicant after: Shanghai Qilu Pharmaceutical Research Center Co.,Ltd. Address before: 250101 No. 317, Xinluo street, high tech Zone, Jinan City, Shandong Province Applicant before: Qilu Pharmaceutical Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant |